Pharmaceuticals
Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm
* Polytaxel, a novel pain-free anticancer drug, may not require break periods * A new standard of care, more convenient than docetaxel, is suggested * Hyundai Bioscience to enter clinical trial on pancreatic cancer in Australia * Patient-centered chemotherapy to enable outpatients to live nor...
2022-11-25 21:00
13202
Venus Medtech to showcase its structural heart treatments at London Valves 2022
The company's growing number of solutions for structural heart disease will be presented at multiple events during the conference betweenNovember 27-29 HANGZHOU, China, Nov. 25, 2022 /PRNewswire/ -- Venus Medtech is building an exciting pipeline of treatments for structural heart disease. The co...
2022-11-25 18:08
8241
Australian Scientists Honoured with the Grand Hamdan Award
DUBAI, UAE, Nov. 25, 2022 /PRNewswire/ -- The Award ceremony of the Sheikh Hamdan bin Rashid Al Maktoum Award for Medical Sciences, hosted in Dubai, took place on 23rd of November the Museum of the Future. The Award celebrated its 12th term (2021-2022) and 22nd year, in the presence of SheikhRas...
2022-11-25 10:39
4194
AstraZeneca Thailand Wins Two ACES Awards 2022: "Industry Champions of the Year" and "Community Initiative"
BANGKOK, Nov. 25, 2022 /PRNewswire/ -- AstraZeneca (Thailand) Co., Ltd., was
recently honoured with two accolades in the categories ofIndustry Champions of
the Year and Community Initiative at the Asia Corporate Excellence &
Sustainability Awards 2022(ACES Awards 2022).
2022-11-25 10:00
5189
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
SHANGHAI, Nov. 24, 2022 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its clinical trial application for 9MW3011 Injection used in patients with polycythemia vera was formally approved by the United States Food...
2022-11-24 21:00
5200
AcuCort signs its first commercial agreement for the company's drug Zeqmelit™
LUND, Sweden, Nov. 24, 2022 /PRNewswire/ -- AcuCort AB (publ) (Spotlight Stock Market: ACUC) today announces that the company has signed an exclusive commercial agreement with the global biopharmaceutical company Kamada Ltd., (NASDAQ: KMDA; TASE: KMDA.TA). The agreement gives Kamada the exclusive...
2022-11-24 00:42
4160
Ascletis Announces IND Approval of Oral 3CLpro Inhibitor ASC11 for COVID-19 by U.S. FDA
--The Phase I clinical trial will consist of 3 cohorts in healthy subjects, including single- and multiple-dose escalation studies and food effect study. The objective of Phase I trial is to find a right dose to move into the pivotal Phase II/III in COVID-19 patients --In antiviral cellular assa...
2022-11-23 19:43
5119
Jiangsu Traditional Chinese Medicine International Exchange Conference kicked off in Nanjing
NANJING, China, Nov. 23, 2022 /PRNewswire/ -- On November 21st, the "Jiangsu Traditional Chinese Medicine International Exchange Conference" jointly sponsored by the Foreign Affairs Office of Jiangsu Provincial People's Government and Jiangsu Health Commission kicked off inNanjing. The theme of t...
2022-11-23 14:19
2866
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
INDIANAPOLIS, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an ...
2022-11-22 20:00
3112
3Z: Zebrafish mutant model reveals novel drug candidates for ADHD
REYKJAVIK, Iceland, Nov. 22, 2022 /PRNewswire/ -- ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, is beneficial for only a subset of patients and can cause side effects including weight loss, insomnia and hypertension. Therefore, the ...
2022-11-22 10:54
3298
Better treatments for breast cancer! Latest Clinical Data of Bispecific Antibodies will be presented at SABCS 2022 By Alphamab Oncology
SUZHOU, China, Nov. 22, 2022 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that results from three clinical studies of KN026 (anti-HER2 bispecific antibody) and KN046 (PD-L1/CTLA4 bispecific antibody) will be presented as Spotlight Poster Discussion or Poster Presentation at t...
2022-11-22 09:18
4875
First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy
MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with rec...
2022-11-22 04:59
3959
IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer
SYDNEY, Nov. 21, 2022 /PRNewswire/ -- Highlights * Clarity's fifth successful Investigational New Drug (IND) application with theUnited States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin * A total of six products with both the diagnostic and t...
2022-11-21 22:04
4559
Cambrex to Acquire Snapdragon Chemistry, a Leader in Continuous Flow API Development Services
EAST RUTHERFORD, N.J., Nov. 21, 2022 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO) providing drug substance, drug product, and analytical services across the entire drug lifecycle, today announced that it has entered into a definitive agreeme...
2022-11-21 19:00
3774
Ainos Publishes Preclinical Data Demonstrating its VELDONA Formulation's Potential as Treatment Candidates for the Most Common Medical Conditions for Companion Animals
VELDONA® interferon-alpha formulation has shown potential as a treatment candidate for feline chronic gingivostomatitis and canine atopic dermatitis Ainos advances its product pipeline as it targets commencing clinical studies during the second quarter of 2023 SAN DIEGO, Nov. 21, 2022 /PRNewswir...
2022-11-21 18:30
2177
OLON, INTERNATIONAL API SUPPLIER, RELEASES THE NEW SUSTAINABILITY REPORT 2022 CONFIRMING THE PROGRESS OF ITS SUSTAINABILITY IN THE FOCUS AREAS OF ENVIRONMENT, SUPPLY CHAIN, PEOPLE, COMMUNITY ENGAGEMENT, PRODUCTION
"Our ambition is to promote a more sustainable production of APIs, meeting the highest standards of quality"Paolo Tubertini, CEO of the Group, commented "To achieve this, we are investing in people, in innovation and technology processes, endorsing the sustainable development goals proposed by th...
2022-11-21 18:00
3132
Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics
CAMBRIDGE, Mass., Nov. 21, 2022 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement with Dragonfly Therapeutics based on Nona...
2022-11-21 17:31
3691
Lianhua Respiratory Health Products to Assure the Smooth Holding of Hainan International Health Industry Expo
SHIJIAZHUANG, China, Nov. 21, 2022 /PRNewswire/ -- The 6th Hainan International Health Industry Expo kicked off onNovember 18th, in Haikou City, China's Hainan Province. With the theme of "Construct a Global Health System, Draw a Beautiful Future for Hainan Free Trade Port", this year's event wil...
2022-11-21 16:42
3052
Jiangsu Recbio Technology Co., Ltd. Increases Production For The First Phase Of Manufacturing Facility With A Maximum Annual Output Of 20 Million Doses Of Recombinant HPV 9-Valent Vaccine
TAIZHOU, China, Nov. 21, 2022 /PRNewswire/ -- (the "Company", together with its subsidiaries, the "Group") on voluntary basis. The board of directors of the Company (the "Board") is pleased to announce that in order to meet the rapidly growing market demand for HPV 9-valent vaccines inChina and ...
2022-11-21 16:07
3939
BGI Group Signs MOUs in Indonesia to Support Genomics Development
SHENZHEN, China, Nov. 21, 2022 /PRNewswire/ -- BGI Group signed three Memorandum of Understandings (MOUs) in the lead up to the G20 Summit inBali with the Indonesian Ministry of Health, the University ofIndonesia and the Del Institute of Technology (Institut Teknologi Del). The MOUs cover geno...
2022-11-21 14:33
3653
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
43748
Cuttable Unveils Next-Generation AI Advertising Platform as U.S. Expansion Accelerates
2026-10-24 00:00
33975
The Future of AI 3D Character Workflows: Reallusion CC 5.2 Turns Meshes into Living Characters
2026-10-29 20:03
19123
ROKAE delivers its 10,000th humanoid force-controlled arm
2026-10-27 00:00
17169
